Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)

Historical Holders from Q1 2023 to Q3 2025

Symbol
ELVN on Nasdaq
Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
59,746,870
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
59,389,507
Holdings value
$1,215,687,864
% of all portfolios
0%
Number of holders
132
Number of buys
77
Number of sells
-42
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 13.4% $140,468,212 7,918,163 ORBIMED ADVISORS LLC 16 Jun 2025
FMR LLC 13.3% $161,103,383 7,870,219 FMR LLC 30 Sep 2025
Commodore Capital LP 9.9% $135,215,385 6,022,957 Commodore Capital LP 30 Jun 2025
Fairmount Funds Management LLC 6.3% -4.3% $83,321,918 +$11,419,103 3,711,444 +16% Fairmount Funds Management LLC 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 5.4% $66,042,996 3,226,331 Venrock Healthcare Capital Partners III, L.P. 30 Sep 2025
BlackRock, Inc. 5.1% $59,005,266 2,941,395 BlackRock, Inc. 30 Jun 2025
Polar Capital Holdings Plc 5.17% +5.6% $56,952,978 +$3,304,932 2,536,881 +6.2% Polar Capital Holdings Plc 30 Jun 2025

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN)

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 59,389,507 $1,215,687,864 -$296,038 $20.47 132
2025 Q2 59,434,902 $1,192,251,085 +$192,194,924 $20.06 123
2025 Q1 49,886,849 $983,923,667 +$4,352,699 $19.68 118
2024 Q4 49,624,914 $1,116,597,658 +$24,828,957 $22.5 111
2024 Q3 47,688,348 $1,218,010,157 -$20,810,259 $25.54 100
2024 Q2 48,318,843 $1,129,194,355 +$91,652,714 $23.37 91
2024 Q1 44,456,336 $780,753,492 +$95,045,035 $17.59 72
2023 Q4 39,000,634 $539,791,932 -$652,659 $13.84 61
2023 Q3 39,076,502 $533,779,750 -$2,178,662 $13.66 60
2023 Q2 39,092,843 $797,915,923 +$112,876,379 $20.41 61
2023 Q1 33,557,749 $734,910,999 +$734,911,000 $21.9 44